Clarithromycin Side Effects and Precautions

Common Side Effects

• The Centers for Disease Control and Prevention recommends monitoring for gastrointestinal symptoms, which are the most common adverse effects of clarithromycin, occurring in approximately 9-11% of patients 1, 2
• Gastrointestinal effects, including abdominal pain, epigastric distress, nausea, vomiting, and diarrhea, are the most frequently reported adverse reactions 1, 2

Serious Side Effects

• The Centers for Disease Control and Prevention notes that hypersensitivity reactions, including skin rashes, drug fever, eosinophilia, and anaphylaxis, can occur with clarithromycin use 1
• The American Thoracic Society recommends caution with clarithromycin use in elderly patients due to the risk of QT prolongation, particularly when used with other medications that prolong the QT interval 3
• The American Thoracic Society also recommends monitoring for signs of myopathy when clarithromycin is used with statins, due to increased risk of toxicity 3

Special Population Considerations

• The Centers for Disease Control and Prevention classifies clarithromycin as FDA Pregnancy Category C, and recommends that it be used during pregnancy only when no alternatives exist 1

Drug Interactions

• The Centers for Disease Control and Prevention notes that clarithromycin inhibits the cytochrome P450 enzyme system, which can increase blood levels of drugs metabolized by this pathway, including statins 1, 2
• The American Thoracic Society recommends avoiding concomitant use of clarithromycin with astemizole, cisapride, pimozide, and terfenadine due to increased risk of QT prolongation and cardiac arrhythmias 1

Monitoring Recommendations

• The Centers for Disease Control and Prevention recommends monitoring for gastrointestinal symptoms, as well as periodic liver function tests, especially in the first 3 months of therapy 1, 2
• The American Thoracic Society recommends monitoring drug levels and effects of medications with potential interactions, including statins, when used with clarithromycin 3

Clarithromycin-Associated Diarrhea

Gastrointestinal Side Effects

• Nausea, vomiting, abdominal pain, and metallic taste are common gastrointestinal side effects of clarithromycin, according to the American Thoracic Society 4

Incidence and Severity

• The CDC guidelines note that diarrhea is among the most common adverse effects associated with clarithromycin when used for treatment of various infections 5

Special Considerations

• Elderly patients with low body weight may require lower doses of clarithromycin to reduce toxicity, including gastrointestinal effects, as recommended by the American College of Chest Physicians 4
• Patients with a history of gastrointestinal disorders may be at higher risk for developing diarrhea with clarithromycin use, according to the American Academy of Respiratory and Critical Care Medicine 4
• When prescribing clarithromycin, clinicians should follow antibiotic stewardship principles to minimize adverse effects, including limiting duration of therapy when possible, as suggested by the American Academy of Dermatology 6

Adverse Effects of Clarithromycin

Gastrointestinal Tolerability

• Certain probiotics and prebiotics show promising results as adjuvant treatment in reducing side effects when clarithromycin is used in H. pylori eradication regimens, though this evidence is of low quality, according to the European Society of Gastrointestinal Endoscopy 7

Clarithromycin‑Associated Diarrhoea: Evidence‑Based Guidance

Risk of Clostridioides difficile Infection

• Clarithromycin disrupts normal gut microbiota, creating a niche for C. difficile overgrowth and can cause CDI even after prolonged low‑dose therapy (e.g., after 20 weeks of treatment)【8】.

Management of Mild Diarrhoea

• For patients with mild diarrhoea (≈3–4 loose stools per day without systemic signs), continuation of clarithromycin is generally appropriate because the symptom is usually self‑limited and does not require drug discontinuation【9】【10】.

Management of Moderate‑Severe or Bloody Diarrhoea

• In cases of moderate‑severe diarrhoea or any watery/bloody stools, clinicians should promptly test for C. difficile toxin and discontinue clarithromycin pending results【8】.
• Such diarrhoea should not be automatically attributed to a benign side effect without excluding CDI, especially in children on long‑term therapy【8】.

British Thoracic Society Guideline Recommendations

• The British Thoracic Society notes that gastrointestinal adverse effects are slightly more frequent with macrolides than with some other antibiotics, but they rarely necessitate cessation of therapy【9】【10】.
• Patients should be counseled at treatment initiation about the possibility of developing gastrointestinal symptoms【9】.
• Ongoing therapy should include monitoring for antimicrobial resistance and consideration of treatment breaks once clinical objectives are achieved【10】.

Clarithromycin Safety, Dosing Limits, and Drug‑Interaction Guidance

Adverse Effects

• Gastro‑intestinal adverse events occur in approximately 9‑11 % of patients receiving clarithromycin; the risk increases with higher daily doses. (U.S. Centers for Disease Control and Prevention 2009) 11
• The most frequent adverse effects are GI symptoms (nausea, vomiting, abdominal pain, metallic taste, diarrhea) caused by a motilin‑like activity that stimulates GI motility. (Thorax 2020) 12
• Elevated liver transaminases have been reported during clarithromycin therapy. (CDC 2009) 11
• Both clarithromycin and azithromycin can prolong the QT interval and are associated with a risk of sudden cardiac death; ECG monitoring is advised when used with other QT‑prolonging agents. (Clinical Infectious Diseases 2020) 13
• Ototoxicity—including hearing loss and tinnitus—has been linked to macrolide use; higher doses in older adults (e.g., 1000 mg twice daily clarithromycin) increase this risk. (Thorax 2020; Clinical Infectious Diseases 2020) [12][13]

Maximum Dose Restrictions

• Daily clarithromycin doses exceeding 1 g (e.g., for disseminated Mycobacterium avium complex) are associated with increased mortality and should be avoided. (CDC 2009) 11

Cardiac Safety Monitoring

• Obtain a baseline electrocardiogram in patients at risk for QT prolongation before initiating clarithromycin. (Clinical Infectious Diseases 2020) 13

Drug‑Interaction Considerations

Rifamycins

• Azithromycin’s serum concentrations are less affected by concurrent rifamycin therapy than clarithromycin’s, making azithromycin the safer option when rifamycins are required. (Clinical Infectious Diseases 2020) 13
• Co‑administration of clarithromycin with rifabutin leads to a bidirectional interaction that raises rifabutin levels and has been associated with uveitis. (Clinical Infectious Diseases 2020) 13
• When rifabutin doses exceed 450 mg/day together with clarithromycin, the risk of uveitis and arthralgias rises. (CDC 2009) 11

Protease Inhibitors (PIs)

• Protease inhibitors increase clarithromycin concentrations; however, current evidence does not define a precise dose‑adjustment protocol. (CDC 2009) 11

Non‑Nucleoside Reverse‑Transcriptase Inhibitors (NNRTIs)

• Efavirenz reduces clarithromycin AUC by ~39 % and nevirapine reduces it by ~35 %; clinicians should monitor for possible treatment failure. (CDC 2009) 11

Comparative Tolerability: Clarithromycin vs. Azithromycin

• Azithromycin is preferred over clarithromycin because it offers better tolerability, fewer CYP3A4‑mediated drug interactions, a lower pill burden, once‑daily dosing, and comparable efficacy. (Clinical Infectious Diseases 2020) [14][13]
• No clinically significant differences have been observed between the two agents regarding sputum culture conversion, overall treatment outcomes, or the emergence of macrolide resistance. (Clinical Infectious Diseases 2020) [14][13]
• If a patient cannot tolerate azithromycin, switching to clarithromycin (or vice‑versa) is an acceptable strategy. (Clinical Infectious Diseases 2020) 13
• In settings where azithromycin is unavailable, clarithromycin remains an acceptable alternative, though clinicians should be vigilant for its greater potential for drug‑drug interactions. (Clinical Infectious Diseases 2020) [14][13]

Key Safety Reminder

• Never exceed a total daily clarithromycin dose of 1 g when treating MAC disease, as higher dosing is linked to increased mortality. (CDC 2009) 11